Akari Therapeutics Plc Stock Fundamentals
| AKTX Stock | USD 1.20 0.01 0.83% |
Akari Therapeutics PLC fundamentals help investors to digest information that contributes to Akari Therapeutics' financial success or failures. It also enables traders to predict the movement of Akari Stock. The fundamental analysis module provides a way to measure Akari Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Akari Therapeutics stock.
At this time, Akari Therapeutics' Interest Expense is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 16.3 M in 2024, whereas Operating Income is likely to drop (17.6 M) in 2024. Akari | Select Account or Indicator |
Akari Therapeutics PLC Company Shares Owned By Insiders Analysis
Akari Therapeutics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Akari Therapeutics Shares Owned By Insiders | 17.91 % |
Most of Akari Therapeutics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Akari Therapeutics PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 17.91099999999999% of Akari Therapeutics PLC are shares owned by insiders. This is 17.99% higher than that of the Pharmaceuticals sector and 26.31% higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is 77.51% lower than that of the firm.
Akari Therapeutics PLC Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Akari Therapeutics's current stock value. Our valuation model uses many indicators to compare Akari Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Akari Therapeutics competition to find correlations between indicators driving Akari Therapeutics's intrinsic value. More Info.Akari Therapeutics PLC is rated fifth in return on equity category among related companies. It is rated fifth in return on asset category among related companies . At this time, Akari Therapeutics' Return On Equity is fairly stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Akari Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Akari Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Akari Therapeutics' earnings, one of the primary drivers of an investment's value.Akari Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Akari Therapeutics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Akari Therapeutics could also be used in its relative valuation, which is a method of valuing Akari Therapeutics by comparing valuation metrics of similar companies.Akari Therapeutics is currently under evaluation in shares owned by insiders category among related companies.
Akari Fundamentals
| Return On Equity | -12.81 | ||||
| Return On Asset | -1.16 | ||||
| Current Valuation | 5.74 M | ||||
| Shares Outstanding | 7.92 M | ||||
| Shares Owned By Insiders | 17.91 % | ||||
| Shares Owned By Institutions | 1.61 % | ||||
| Number Of Shares Shorted | 10.52 K | ||||
| Price To Earning | (2.15) X | ||||
| Price To Book | 3.07 X | ||||
| EBITDA | (16.8 M) | ||||
| Net Income | (10.01 M) | ||||
| Cash And Equivalents | 8.15 M | ||||
| Cash Per Share | 0.14 X | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.73 X | ||||
| Book Value Per Share | (0.04) X | ||||
| Cash Flow From Operations | (16.43 M) | ||||
| Short Ratio | 0.76 X | ||||
| Earnings Per Share | (2.04) X | ||||
| Target Price | 80.0 | ||||
| Beta | 0.97 | ||||
| Market Capitalization | 9.59 M | ||||
| Total Asset | 4.36 M | ||||
| Retained Earnings | (227.46 M) | ||||
| Working Capital | 1.77 M | ||||
| Current Asset | 69.66 M | ||||
| Current Liabilities | 21.12 M | ||||
| Net Asset | 4.36 M |
About Akari Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Akari Therapeutics PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Akari Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Akari Therapeutics PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 0.00 | 0.00 | |
| Cost Of Revenue | 4 K | 4.4 K | |
| Stock Based Compensation To Revenue | 0.00 | 0.00 | |
| Sales General And Administrative To Revenue | 0.00 | 0.00 | |
| Research And Ddevelopement To Revenue | 0.00 | 0.00 | |
| Capex To Revenue | 0.00 | 0.00 | |
| Revenue Per Share | 0.00 | 0.00 | |
| Ebit Per Revenue | 0.00 | 0.00 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Akari Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Akari Therapeutics' short interest history, or implied volatility extrapolated from Akari Therapeutics options trading.
Pair Trading with Akari Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Akari Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akari Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Akari Stock
| 0.8 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
Moving against Akari Stock
| 0.85 | DSGN | Design Therapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.77 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.76 | ERNA | Eterna Therapeutics | PairCorr |
| 0.74 | LLY | Eli Lilly Sell-off Trend | PairCorr |
| 0.73 | CRL | Charles River Labora Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to Akari Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Akari Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Akari Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Akari Therapeutics PLC to buy it.
The correlation of Akari Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Akari Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Akari Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Akari Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Akari Therapeutics Piotroski F Score and Akari Therapeutics Altman Z Score analysis. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Akari Stock analysis
When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
Is Akari Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akari Therapeutics. If investors know Akari will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akari Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.04) | Return On Assets (1.16) | Return On Equity (12.81) |
The market value of Akari Therapeutics PLC is measured differently than its book value, which is the value of Akari that is recorded on the company's balance sheet. Investors also form their own opinion of Akari Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akari Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akari Therapeutics' market value can be influenced by many factors that don't directly affect Akari Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akari Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akari Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akari Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.